Dermatological toxicity associated with the use of gilteritinib in relapsed acute myeloid leukemia with FLT3 mutation: a case report

被引：0

作者：

Roldan, Alicia Martin ^{[1
]}

Alarcon-Payer, Carolina ^{[1
]}

Suarez, Maria Del Mar Sanchez ^{[1
]}

Morales, Alberto Jimenez ^{[1
]}

机构：

[1] Hosp Univ Virgen Nieves, Hosp Pharm Dept, Granada 18014, Spain

来源：

ANTI-CANCER DRUGS | 2024年 / 35卷 / 09期

关键词：

FLT3; mutation; gilteritinib; granuloma annulare; neutrophilic dermatosis; relapsed/refractory AML; CHEMOTHERAPY; THERAPY;

D O I：

10.1097/CAD.0000000000001634

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We present a case of a patient diagnosed with FLT3 mut+ acute myeloid leukemia with FLT3 and NMP1 mutations who did not respond to standard induction and consolidation treatment with chemotherapy. Due to the FLT3mut+ gene mutation and intermediate cytogenetic risk, treatment with gilteritinib is requested. After treatment she experienced a neutrophilic dermatosis and granuloma annulare that was resolved with gilteritinib dose reduction and specific treatment in coordination with the dermatology department.

引用

页码：872 / 874

页数：3

共 50 条

[41] FLT3 inhibitors: clinical potential in acute myeloid leukemia
Hospital, Marie-Anne
Green, Alexa S.
Maciel, Thiago T.
Moura, Ivan C.
Leung, Anskar Y.
Bouscary, Didier
Tamburini, Jerome
ONCOTARGETS AND THERAPY, 2017, 10 : 607 - 615
[42] Incidence and clinical significance of FLT3 and nucleophosmin mutation in childhood acute myeloid leukemia in Chile
Cabrera, Maria Elena
Monardes, Virginia
Salgado, Carmen
Cares, Carolina
Gonzalez, Claudio
HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2023, 45 (01) : 77 - 82
[43] The safety profile of FLT3 inhibitors in the treatment of newly diagnosed or relapsed/refractory acute myeloid leukemia
Marconi, Giovanni
Giannini, Maria Benedetta
Bagnato, Gianmarco
Simonetti, Giorgia
Cerchione, Claudio
Mosquera Orgueira, Adrian
Musuraca, Gerardo
Martinelli, Giovanni
EXPERT OPINION ON DRUG SAFETY, 2021, 20 (07) : 791 - 799
[44] Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive
Garcia, J. S.
Percival, M. E.
DRUGS OF TODAY, 2017, 53 (10) : 531 - 543
[45] Mutation of FLT3 gene in acute myeloid leukemia with normal cytogenetics and its association with clinical and immunophenotypic features
Chauhan, Pradeep S.
Bhushan, Bharat
Mishra, Ashwani K.
Singh, Laishram C.
Saluja, Sumita
Verma, Saurabh
Gupta, Dipendra K.
Mittal, Vishakha
Chaudhry, Sumita
Kapur, Sujala
MEDICAL ONCOLOGY, 2011, 28 (02) : 544 - 551
[46] Targeting on glycosylation of mutant FLT3 in acute myeloid leukemia
Hu, Xiaoli
Chen, Fangyuan
HEMATOLOGY, 2019, 24 (01) : 651 - 660
[47] Ningetinib, a novel FLT3 inhibitor, overcomes secondary drug resistance in acute myeloid leukemia
Hu, Chuhong
Zhang, Yvyin
Yang, Jie
Xu, Yanli
Deng, Tingfen
Li, Yumiao
Xu, Shilin
Wang, Shunqing
Wang, Peihong
CELL COMMUNICATION AND SIGNALING, 2024, 22 (01)
[48] Single institute study of FLT3 mutation in acute myeloid leukemia with near tetraploidy in Serbia
Vladimir Jurišić
Sonja Pavlović
Nataša Čolović
Vesna Djordjevic
Vera Bunjevački
Gradimir Janković
Milica Čolović
Journal of Genetics, 2009, 88 : 149 - 152
[49] Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin
Arnan Sangerman, Montserrat
Fernandez Moreno, Ainhoa
Garcia Quintana, Antonio
Garcia-Vidal, Carolina
Olave Rubio, Maria Teresa
Tormo Diaz, Maria Del Mar
Vendranas, Meritxell
Rodriguez Macias, Gabriela
EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (03) : 203 - 214
[50] Dual Inhibition of FLT3 and AXL by Gilteritinib Overcomes Hematopoietic Niche-Driven Resistance Mechanisms in FLT3-ITD Acute Myeloid Leukemia
Dumas, Pierre-Yves
Villacreces, Arnaud
Guitart, Amelie V.
El-habhab, Ali
Massara, Layal
Mansier, Olivier
Bidet, Audrey
Martineau, Delphine
Fernandez, Solene
Leguay, Thibaut
Pigneux, Arnaud
Vigon, Isabelle
Pasquet, Jean-Max
Desplat, Vanessa
CLINICAL CANCER RESEARCH, 2021, 27 (21) : 6012 - 6025

← 1 2 3 4 5 →